Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 2
ClinicalTrials.gov
A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis.(ELIVATE)
INTERVENTIONAL
Inicio: 30 de dic de 2019
ID: NCT04065841
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
INTERVENTIONAL
Inicio: 14 de nov de 2024
ID: NCT06664801
Reclutando
ClinicalTrials.gov
Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires
OBSERVATIONAL
Inicio: 1 de ene de 2017
ID: NCT01501838
Completado
Fase 2
ClinicalTrials.gov
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
INTERVENTIONAL
Inicio: 1 de mar de 2009
ID: NCT00743938
Aún no recluta
Fase 3
ClinicalTrials.gov
A Study to Evaluate the Dose-exposure, Safety, and Exploratory Efficacy of Nerandomilast in Children and Adolescents From 2 Years to Less Than 18 Years of Age With Fibrosing Interstitial Lung Disease (Part A: Double-blind, Placebo-controlled in Children From 6 to Less Than 18 Years of Age and Open-label Active Treatment in Children From 2 to Less Than 6 Years of Age), Followed by an Open-label Phase With Active Treatment (Part B)
INTERVENTIONAL
Inicio: 6 de jul de 2026
ID: NCT07366034
Completado
Fase 3
ClinicalTrials.gov
Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD
INTERVENTIONAL
Inicio: 15 de oct de 2014
ID: NCT02257385
Completado
Fase 3
ClinicalTrials.gov
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
INTERVENTIONAL
Inicio: 17 de ene de 2017
ID: NCT02999178
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma
INTERVENTIONAL
Inicio: 30 de jun de 2022
ID: NCT05421598
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients
INTERVENTIONAL
Inicio: 30 de mar de 2021
ID: NCT04672564
Completado
Fase 3
ClinicalTrials.gov
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
INTERVENTIONAL
Inicio: 5 de ago de 2014
ID: NCT02134028
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization
INTERVENTIONAL
Inicio: 1 de sept de 2012
ID: NCT01530763
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
INTERVENTIONAL
Inicio: 22 de jul de 2022
ID: NCT05321420
Completado
Fase 3
ClinicalTrials.gov
Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)
INTERVENTIONAL
Inicio: 18 de sept de 2015
ID: NCT02474355
Activo, no recluta
Fase 2
ClinicalTrials.gov
KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
INTERVENTIONAL
Inicio: 6 de dic de 2022
ID: NCT05445843
Terminado
Fase 3
ClinicalTrials.gov
Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis
INTERVENTIONAL
Inicio: 31 de ago de 2015
ID: NCT02456103
Completado
ClinicalTrials.gov
Mechanical Power Normalized to Compliance in Patients With Acute Respiratory Distress Syndrome
OBSERVATIONAL
Inicio: 1 de mar de 2016
ID: NCT05761626
Completado
Fase 2
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Dose-ranging Study to Evaluate GSK573719 in Combination With Fluticasone Furoate, Fluticasone Furoate Alone, and an Active Control of Fluticasone Furoate/Vilanterol Combination in Subjects With Asthma
INTERVENTIONAL
Inicio: 3 de abr de 2012
ID: NCT01573624
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
INTERVENTIONAL
Inicio: 11 de dic de 2020
ID: NCT04652518
Completado
ClinicalTrials.gov
Evolution of Quality of Life, Functional Capacity, Nutritional Status and Return to Work Activity in Patients Admitted for Severe Pneumonia Due to COVID 19 Requiring Invasive Mechanical Ventilation
OBSERVATIONAL
Inicio: 1 de jun de 2020
ID: NCT06727474
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
INTERVENTIONAL
Inicio: 28 de may de 2020
ID: NCT04376684
Anterior
1
...
9
10
11
...
434
Siguiente
Filtros